ASCO GU 2023

Bladder preservation strategies - promising data but no…

Robust DFS benefit, but lack of OS data leaves open…

No final OS difference - but subgroups may benefit from…

Re-shaping bladder cancer treatment

Atezo monotherapy for mUC

IMvigor130: final OS

Update / German Real World Data M1 BC

Final OS data show no significant benefit for chemo…

No change in SoC, but new genomic predictors for EV…

Pembro for HR NMIBC

PD-1 as combo in 1st line

Benefit of neoadjuvant pembro for CE and CI patients

Final overall survival

Urothelial cancer - hidden gems of the poster session

Exciting survival data for adjuvant NIVO

3 yrs outcome of Nivo for adjuvant therapy

The bladder cancer highlights of ASCO GU

NMIBC highlights from ASCO GU23

Pembrolizumab in HR NIMBC

Checkpoint inhibition in adjuvant therapy

Impressive DFS with adjuvant Nivo in biomarker-positive…

The bladder cancer highlights of ASCO GU

Los aspectos más destacados del ASCO GU 2023 en cáncer…

Refinando el tratamiento del cancere vejiga

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την…

BCG yanıtsız yüksek riskli KİOMK tedavisinde…

Triplet combination - all-comer therapy or high risk…

Benefits and risks of precision medicine with PARPi

Monotherapy is not any longer standard of care

Controversy in ADT roundtable

ARASENS - post-hoc subgroup analysis

Normal baseline testosterone level is a strong…

mHSPC - new standard and more insights

Intensification of salvage therapy in high risk…

New ways to target androgen receptor signaling

Formula 509: Racing to a better straegy for…

Doublet or all-in: the solution for all patients?

MMAI - a superior prognostic marker for high risk…

PARP and testing

ARASENS: triple independent of volume and risk

Surgery vs. Radiation for N1 PCa: who wins?

PARPi combination in mCRPC

Tiebreaker for previous trials

PARPi study with different design

Rucaparib: treatment option for biomarker-selected…

Propel - final OS

Rucaparib - the new player?

PARPi & ARPi with wonderful data

PARPi combo: all-comer treatment for mCRPC

TALA ENZO with improved PFS in mCRPC

TALA in 1st line for all patients with mCRPC

Rucaparib - ready for clinical practice in BRCAmut…

Encouraging results for Talazoparib

PARPi combo approval for all-comers - balancing…

MMAI- Yüksek riskli prostat kanserinde üstün bir…

Nya vägar att blockera androgenreceptor signalering

miR371'in orşiektomi sonrası tedavi seçimini…

RP sonrası kurtarma RT ile GnRH Analog ABİ APA…

Ny PARP hämmar studie med anna design

edavi öncesi normal testosteron seviyesi ADT sonrası…

Lokalize prostat kanserinde cerrahi ile SBRT…

PARPi & ARPi με υπέροχα δεδομένα

Theranostics in RCC - usefull tools for ccRCC?!

Updated data of CheckMate 9ER - impact on real-world…

Outcomes of patients with brain metastases treated with…

Zircon-PET in RCC

Hypothesis-generating differences in risks groups

First prospective data on 2nd line therapy after IO…

New therapy choices for renal cell cancer patients

Longer FU confirms significant benefit of Nivo-Cabo,…

Refining prediction of stage I seminoma

microbiom & CPI perspectives